Jolien J Tjalma1, P Beatriz Garcia-Allende2, Elmire Hartmans1, Anton G Terwisscha van Scheltinga3, Wytske Boersma-van Ek1, Jürgen Glatz2, Maximilian Koch2, Yasmijn J van Herwaarden4, Tanya M Bisseling4, Iris D Nagtegaal5, Hetty Timmer-Bosscha6, Jan Jacob Koornstra1, Arend Karrenbeld7, Jan H Kleibeuker1, Gooitzen M van Dam8, Vasilis Ntziachristos2, Wouter B Nagengast9. 1. Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Chair for Biological Imaging & Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center Munich, Munich, Germany. 3. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and. 8. Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 9. Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands w.b.nagengast@umcg.nl.
Abstract
UNLABELLED: Small and flat adenomas are known to carry a high miss-rate during standard white-light endoscopy. Increased detection rate may be achieved by molecular fluorescence endoscopy with targeted near-infrared (NIR) fluorescent tracers. The aim of this study was to validate vascular endothelial growth factor A (VEGF-A) and epidermal growth factor receptor (EGFR)-targeted fluorescent tracers during ex vivo colonoscopy with an NIR endoscopy platform. METHODS: VEGF-A and EGFR expression was determined by immunohistochemistry on a large subset of human colorectal tissue samples--48 sessile serrated adenomas/polyps, 70 sporadic high-grade dysplastic adenomas, and 19 hyperplastic polyps--and tissue derived from patients with Lynch syndrome--78 low-grade dysplastic adenomas, 57 high-grade dysplastic adenomas, and 31 colon cancer samples. To perform an ex vivo colonoscopy procedure, 14 mice with small intraperitoneal EGFR-positive HCT116(luc) tumors received intravenous bevacizumab-800CW (anti-VEGF-A), cetuximab-800CW (anti-EGFR), control tracer IgG-800CW, or sodium chloride. Three days later, 8 resected HCT116(luc) tumors (2-5 mm) were stitched into 1 freshly resected human colon specimen and followed by an ex vivo molecular fluorescence colonoscopy procedure. RESULTS: Immunohistochemistry showed high VEGF-A expression in 79%-96% and high EGFR expression in 51%-69% of the colorectal lesions. Both targets were significantly overexpressed in the colorectal lesions, compared with the adjacent normal colon crypts. During ex vivo molecular fluorescence endoscopy, all tumors could clearly be delineated for both bevacizumab-800CW and cetuximab-800CW tracers. Specific tumor uptake was confirmed with fluorescent microscopy showing, respectively, stromal and cell membrane fluorescence. CONCLUSION: VEGF-A is a promising target for molecular fluorescence endoscopy because it showed a high protein expression, especially in sessile serrated adenomas/polyps and Lynch syndrome. We demonstrated the feasibility to visualize small tumors in real time during colonoscopy using a NIR fluorescence endoscopy platform, providing the endoscopist a wide-field red-flag technique for adenoma detection. Clinical studies are currently being performed in order to provide in-human evaluation of our approach.
UNLABELLED: Small and flat adenomas are known to carry a high miss-rate during standard white-light endoscopy. Increased detection rate may be achieved by molecular fluorescence endoscopy with targeted near-infrared (NIR) fluorescent tracers. The aim of this study was to validate vascular endothelial growth factor A (VEGF-A) and epidermal growth factor receptor (EGFR)-targeted fluorescent tracers during ex vivo colonoscopy with an NIR endoscopy platform. METHODS:VEGF-A and EGFR expression was determined by immunohistochemistry on a large subset of human colorectal tissue samples--48 sessile serrated adenomas/polyps, 70 sporadic high-grade dysplastic adenomas, and 19 hyperplastic polyps--and tissue derived from patients with Lynch syndrome--78 low-grade dysplastic adenomas, 57 high-grade dysplastic adenomas, and 31 colon cancer samples. To perform an ex vivo colonoscopy procedure, 14 mice with small intraperitoneal EGFR-positive HCT116(luc) tumors received intravenous bevacizumab-800CW (anti-VEGF-A), cetuximab-800CW (anti-EGFR), control tracer IgG-800CW, or sodium chloride. Three days later, 8 resected HCT116(luc) tumors (2-5 mm) were stitched into 1 freshly resected human colon specimen and followed by an ex vivo molecular fluorescence colonoscopy procedure. RESULTS: Immunohistochemistry showed high VEGF-A expression in 79%-96% and high EGFR expression in 51%-69% of the colorectal lesions. Both targets were significantly overexpressed in the colorectal lesions, compared with the adjacent normal colon crypts. During ex vivo molecular fluorescence endoscopy, all tumors could clearly be delineated for both bevacizumab-800CW and cetuximab-800CW tracers. Specific tumor uptake was confirmed with fluorescent microscopy showing, respectively, stromal and cell membrane fluorescence. CONCLUSION:VEGF-A is a promising target for molecular fluorescence endoscopy because it showed a high protein expression, especially in sessile serrated adenomas/polyps and Lynch syndrome. We demonstrated the feasibility to visualize small tumors in real time during colonoscopy using a NIR fluorescence endoscopy platform, providing the endoscopist a wide-field red-flag technique for adenoma detection. Clinical studies are currently being performed in order to provide in-human evaluation of our approach.
Authors: Ray R Zhang; Alexandra B Schroeder; Joseph J Grudzinski; Eben L Rosenthal; Jason M Warram; Anatoly N Pinchuk; Kevin W Eliceiri; John S Kuo; Jamey P Weichert Journal: Nat Rev Clin Oncol Date: 2017-01-17 Impact factor: 66.675
Authors: Joshua J Yim; Stefan Harmsen; Krzysztof Flisikowski; Tatiana Flisikowska; Hong Namkoong; Megan Garland; Nynke S van den Berg; José G Vilches-Moure; Angelika Schnieke; Dieter Saur; Sarah Glasl; Dimitris Gorpas; Aida Habtezion; Vasilis Ntziachristos; Christopher H Contag; Sanjiv S Gambhir; Matthew Bogyo; Stephan Rogalla Journal: Proc Natl Acad Sci U S A Date: 2021-01-05 Impact factor: 11.205
Authors: Lindsay S Moore; Eben L Rosenthal; Esther de Boer; Andrew C Prince; Neel Patel; Joshua M Richman; Anthony B Morlandt; William R Carroll; Kurt R Zinn; Jason M Warram Journal: Mol Imaging Biol Date: 2017-08 Impact factor: 3.488
Authors: Fabio Feroldi; Mariska Verlaan; Helene Knaus; Valentina Davidoiu; Danielle J Vugts; Guus A M S van Dongen; Carla F M Molthoff; Johannes F de Boer Journal: Biomed Opt Express Date: 2018-11-13 Impact factor: 3.732
Authors: Mehdi Azizi; Hassan Dianat-Moghadam; Roya Salehi; Masoud Farshbaf; Disha Iyengar; Samaresh Sau; Arun K Iyer; Hadi Valizadeh; Mohammad Mehrmohammadi; Michael R Hamblin Journal: Adv Funct Mater Date: 2020-03-03 Impact factor: 18.808
Authors: Stephan Rogalla; Krzysztof Flisikowski; Dimitris Gorpas; Aaron T Mayer; Tatiana Flisikowska; Michael J Mandella; Xiaopeng Ma; Kerriann M Casey; Stephen A Felt; Dieter Saur; Vasilis Ntziachristos; Angelika Schnieke; Christopher H Contag; Sanjiv S Gambhir; Stefan Harmsen Journal: Adv Funct Mater Date: 2019-10-10 Impact factor: 18.808